Subscribe
type here...
Subscribe

Tag: Small Molecule

3D deep-learning research company Charm Therapeutics launches with $50m series A

Global Markets Pharma -
CHARM Therapeutics (“CHARM”, “The Company”), announces today a $50M Series A financing co-led by F-Prime Capital and OrbiMed, with...

BMS, Merck enter into $2.3 billion partnership with Amphista to discover and develop small molecule protein degraders

Drug Development Pharma -
Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, May...

Glenmark received approval to conduct clinical trials of its small molecule on patients with solid tumors and Hodgkin’s lymphoma

Global Markets Pharma -
Glenmark Pharmaceuticals Limited, an innovation-driven, the global pharmaceutical company announced that its subsidiary Glenmark Specialty S.A. (Glenmark) received approval...

ONO and Iktos collaboration in the discovery and development of a new small molecule compounds by using an AI platform and know-how

Global Markets Pharma -
Ono Pharmaceutical Co., Ltd. announced today that it entered into a collaboration agreement with Iktos to discover and develop...

LifeMine and GSK sign cooperation agreement to search for small molecules

Global Markets Pharma -
LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today...

Philochem and Bracco Imaging announce collaboration on development of a small molecule

Drug Development Pharma -
Philochem, a subsidiary of the Philogen Group, and Bracco Imaging On Tuesday announced that they have entered into a...

PHARMPROM is a premier digital resource for the pharmaceutical sector, combining breaking news, deep insights, and key market events. We cover the entire product lifecycle—from R&D and manufacturing to distribution—in strict accordance with Good Pharmaceutical Practices (GxP).

Disclaimer All content on pharmprom.net is for informational purposes only and does not constitute medical advice. The materials are intended exclusively for industry professionals and are not addressed to the general public.

Company

Headlines

Newsletter

Get important news delivered directly to your inbox and stay connected!

© PHARMPROM 2026